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1. ABSTRACT 
 
Studying Genetic and Enzymatic Constraints Driving Evolution of Antibiotic 
Resistance 
YUSUF TALHA TAMER 
MSc. 2014 
Erdal Toprak (Thesis Supervisor) 
Keywords: Antibiotic Resistance, Bacterial Evolution, Trimethoprim, Morbidostat 
 World is heading towards a post-antibiotic era due to emergence of antibiotic 
resistance. Several fatal infectious diseases caused by antibiotic resistant bacteria cannot 
be treated anymore using the existing antibiotic surplus. Novel antibiotics or novel 
strategies to use antibiotic more efficiently are therefore crucial to combat against 
resistance. However, both of these approaches require a clear understanding of 
antibiotic resistance at molecular and genetic levels. Here in this study, we studied 
evolutionary dynamics of trimethoprim resistance under dynamically sustained drug 
selection. Using a custom made continuous culture device that we call the Morbidostat; 
we evolved drug sensitive Escherichia coli cells against increasing levels of 
trimethoprim adapting strong or mild dilution rates. First, using Illumina whole genome 
sequencing and Sanger sequencing, we identified trimethoprim resistance conferring 
mutations in dihydrofolate reductase (folA) gene and the order that these mutations 
appear in the population. Our results suggest that clonal interference between different 
genotypes is common and longer under strong dilution where trimethoprim stress is 
applied in shorter and steeper pulses. Second, we cloned and purified dihydrofolate 
reductase (DHFR) enzymes with single mutations and carried out biochemical assays to 
quantify mutant enzymes’ enzymatic activities. Our preliminary results showed that 
DHFR mutants have slightly worse substrate affinity (higher km values) but up to ~20 
fold elevated catalysis rate (kcat/km) compared to their wild type ancestor. We conclude 
that trimethoprim-resistance-conferring DHFR mutations decrease affinity to both 
enzyme’s substrate and competing drug molecules, yet enzymatic activity, which is 
essential for folic acid synthesis, is still adequately efficient to maintain bacterial 
fitness. 
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2. ÖZET (IN TURKISH) 
Antibiyotik Direncinin Evrilmesine Yol Açan Genetik Ve Enzimatik Etkenlerin 
İncelenmesi 
Yusuf Talha TAMER 
Yüksek Lisans Tezi 2014 
Anahtar Kelimeler: Antibiyotik Direnci Kazanılması, Trimetoprim, Folat Sentez Yolağı 
 Günümüz dünyası bakterilerin antimikrobiyal ilaçlara direnç kazanması nedeniyle 
antibiyotiklerin tamamıyla etkisiz hale geleceği güne doğru bir geçiş yaşıyor. Bir çok 
ölümcül bulaşıcı hastalık antibiyotiklere dirençli hale gelmiş bakteriler nedeniyle yakın 
gelecekte tedavisiz kalacak. Yeni antibiyotikler ve yeni tedavi yöntemlerinin 
geliştirilmesi ve bunlarla beraber antibiyotik direnci kazanılmasının önüne geçilmesi 
çok büyük önem taşıyor. Bu problemin çözülmesi adına yapılması gereken bakterilerin 
antibiyotik direnci kazanması işleminin genetik ve moleküler aşamalarını anlamak. Bu 
çalışmada trimetoprim antibiyotiğine karşı direnç kazanılmasının evrimsel temellerini 
farklı seçilim baskıları altında inceledik. Bu amaç doğrultusunda bakterilerin eşit bir 
şekilde seçilim baskılarıyla karşılaşmasına ve bakteri büyümesinin sürekli kontrol 
altında tutulmasına izin verebilen Morbidostat adlı makineyi kullandık. Bakteriler güçlü 
(Uzun süreli antibiyotik enjeksiyonuna) ve zayıf (kısa süreli antibiyotik enjeksiyonu) 
olmak üzere iki farklı seçilim baskısı altında antibiyotik direnci kazandılar. İllumina 
tüm genom sekanslama ve Sanger gen sekanslanması yöntemleriyle öncelikle deneyin 
sonucunda direnç kazanılmasına yol açan mutasyonları belirledik, sonrasında 
dihidrofolat reduktaz enzimi üzerinde görmüş olduğumuz bu mutasyonların, hangi 
sırayla kazanıldığını anlamak için günlük alınmış olan örnekleri sekansladık. 
Sonuçlarımızda güçlü seçilim baskısı altındaki popülasyonlarda genotipik çeşitlilik, 
zayıf seçilim gösteren popülasyonlara göre daha uzun süreli ve yaygın olarak görüldü. 
İkinci olarak gördüğümüz bu mutasyonları birer birer yabanıl protein üzerinde 
değişikliğe uğratıp deneyde gördüğümüz mutasyonların reaksiyonun biyokimyasına 
etkisini çalıştık. Elimizdeki ilk sonuçlar gösterdi ki; mutant proteinler yabanıl olanla 
karşılaştırıldığında, substrat affinitesi (Km) adına biraz kötü olsa da reaksiyonun 
katalizinde (Kcat/Km) 20 kata kadar daha etkili oldular. Sonuç olarak trimethoprim 
direnci kazanılmasında gerekli mutasyonlar, enzimin substratına karşı ilgisini azaltmış 
olsa da bakterinin hayatını devam ettirmesi adına çok önemli olan folat sentez yolunun 
çalışmasında daha etkili oldukları için bakteri popülasyonlarının Darwinsel uyumunu 
sağlamış oldular. 
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4. AIM OF STUDY  
World is heading towards a post-antibiotic era due to emergence of antibiotic resistance. 
Several fatal infectious diseases caused by antibiotic resistant bacteria cannot be treated 
anymore using the existing antibiotic surplus. Novel antibiotics or novel strategies to 
use antibiotic more efficiently are therefore crucial to combat against resistance. 
However, both of these approaches require a clear understanding of antibiotic resistance 
at molecular and genetic levels. Here in this study, we studied evolutionary dynamics of 
trimethoprim resistance under dynamically sustained drug selection. 
 
5. INTRODUCTION 
 
5.1. Antibiotics 
 Bacterial pathogens cause severe infections and deaths over 17 million people 
annually.[1] Antibiotics are the substances that inhibit the growth of bacteria or kill 
them directly. They can be produced naturally or synthetically. From the time, 
Alexander Fleming first found antibiotic -Penicillin-, there are hundreds of molecules 
are designed as bactericidal or bacteriostatic agents but only a few of them are 
commercialized because of economical and safety issues. 
5.2. Classification of Antibiotics 
 Commercial antibiotics are classified under 5-6 major classes with respect to their 
target mechanism. Some of these major classes are: Cell Wall Synthesis Inhibitors (e.g. 
β-Lactams), Protein Synthesis Inhibitors (e.g. Aminoglycosides, Macrolides), DNA 
Replication and Repair Inhibitors, Folic Acid Pathway Inhibitors. Beta-Lactam 
antibiotics hold the largest share in the antibiotic market of entire world [2]. Major 
targets of the β-Lactams are peptidoglycan layers and syntheses of the cell wall. This 
class of antibiotics has a special Lactam ring on their chemical structure. The other 
class, Protein synthesis inhibitors, is targeting the ribosomal small and large subunits 
with mimicking substances that have roles in the machinery of translation. Main targets 
for DNA replication and repair inhibitors are DNA and RNA synthesis precursors such 
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as DNA Gyrase Family proteins. Quinolones –synthetics antibiotics - and Coumarins 
are belonged to this group.  Also there are some other targets of antibiotics directly or 
indirectly affecting or blocking the polymerization of nucleic acids and division of cell. 
Folic acid synthesis pathway inhibitors are in this group. Folic acid pathway inhibitors 
will be explained deeply at the second chapter of this thesis. But briefly this pathway 
synthesizes the precursors of nucleic acids. 
 
Figure 1: General Classification of Antibiotics by their targets. Figure is taken from 
http://www.orthobullets.com/basic-science/9059/antibiotic-classification-and-mechanism 06/01/2014[3] 
5.3. Adaptation and Genetic Diversity  
 Rivoire et al states that, there are three foundations that justify adaptations under 
the rules of natural selection:  
1. Populations composed of individuals from diverse genetic backgrounds 
2. These diverse characteristics associate with their fitnesses. 
3. These characteristics should pass to the new generations. [4] 
 There are factors that facilitate adaptation process such as sexual reproduction, 
horizontal gene transfer, and mutation. Among these factors, Clune et al defines 
mutation as the ultimate source for diversification of genotypes. Thus to be able to 
understand the rate of evolution, the rate of mutation is an inevitable criterion [5]. 
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Especially for prokaryotic species mutations are the major effectors that change the 
fitness and the surveillance of the organism.  
 
5.4. Antibiotic Resistance 
 
 
Figure 2: Number of Multi Drug Resistant Tuberculosis (TB) cases observed in world. 
  
 One of the fundamental features of living organisms is responding to an 
environmental or an inner signal. Right after the clinical usage of first antibiotics, 
bacteria started to respond this environmental stress and begin adapting this new 
environment. Though the resistance causing factors are differing among different 
species, there are 7 main factors that facilitate the tolerance of antibiotic stress.  
1. Activated Specific/Non-specific efflux pumps that can control the outflow of 
antibiotics  
2. Modifications in cell wall structures that restrict or block the influx of antibiotics. 
For example altered peptidoglycan structure found in Vancomycin resistant 
enterococcus (VRE). 
3. Some species of bacteria have naturally insensitive target enzymes so they 
practically resistant to antibiotics. This case will be explained later in TMP 
resistance part.  
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4. Post-transcriptional or post-translational modifications may take place on target 
enzyme that make bacteria tolerate the antibiotic or decrease the effects of it. 
5. Horizontal gene transfer of resistant protein or resistance cassette makes 
bacterium become resistant 
6. Covering the environment with biofilm is also a big problem that makes 
bacterium get rid of the effects of antibiotics. 
7. Last but the most important cause that makes bacterium resistant is to mutate 
regulatory or coding region of the target protein. 
 Last reason is the most problematic one between them because it makes not just 
one colony of bacteria resistant; this cause makes them have fitness advantage among 
other colonies. Thus, after certain amount of antimicrobial stress mutated bacteria 
become dominant among the ecosystem [6]. 
 
5.5. Folic Acid Pathway and DHFR  
Figure 3: Folic acid pathway and targets of antibiotic found on this pathway 
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 Studies on folic acid synthesis pathway are going back to observations of Woods 
in 1940 [7]. Folic acid pathway is one of the most crucial pathways for synthesizing 
different kinds of cellular components in both eukaryotes and prokaryotes. For example, 
synthesis of purines such as thymine, and synthesis of aminoacids such as methionine, 
glutamic acid, and glycine are dependent to this pathway. What makes this pathway 
important is all the microorganisms and plant synthesize their folate through folate 
biosynthesis pathway but in mammals instead of just having this pathway; they also 
have folate pumps on their membranes. Mammals can bypass the folic acid pathway by 
just importing the folate from extracellular matrix through the specialized pumps.  
Because of its clinical and commercial importance in antibiotic market, most of the 
enzymes in this pathway are crystallized [8]. Folic Acid Biosynthesis Pathway has two 
main checkpoints controlled by two different classes of antibiotics.  
1. The first reaction is catalyzed by Dihydropteroate Synthase (DHPS) can be 
blocked by Sulfonamides class of antibiotics;  
2. Trimethoprim can block the last reaction, which is catalyzed by Dihydrofolate 
Reductase (DHFR). This project is focused on the enzyme DHFR because of its 
important role on TMP resistant bacterial evolution. In E. coli DHFR is one 
chained and 159 amino acids-containing enzyme.  
5.6. DHFR Enzyme Activity  
Figure 4: Reaction catalyzed by Dihydrofolate Reductase. From Dihydrofolate to 
Tetrahydrofolate [9] 
 
 As shown in the pathway above, DHFR enzyme takes DHF as an input and gives 
THF as product. When we analyze the reaction in deep, there is a methyl group 
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shuttling occurs on DHF molecule (As shown in the right side of the figure). After this 
reaction THF can be further converted to Nucleic acids such as Thymine and certain 
amino acids like Methionine. In their JBC paper, Appleman et al, shows that on E. coli 
DHFR, 27th residue (Aspartic Acid) has an important role as active site [10]. D27 is 
interacting with DHF and helps catalysis of the reaction.  
  
5.7. Trimethoprim: A Folic Acid Pathway inhibiting Antimicrobial Agent 
 Trimethoprim is a synthetic bacteriostatic antibiotic that targets on Dihydrofolate 
Reductase (DHFR) enzyme. This antibiotic first used successfully in a Proteus genus of 
bacteria in 1964 [11]. From that time to now, Trimethoprim is a commonly prescribed 
antibiotic either alone or combination with sulfamethoxazole (SMX) or co-methoxazole 
especially for the urinary tract infections. Since combination therapies with co-
methoxazole later found that has side effects on bone marrows and lose its efficacy as 
antibiotic, this combination therapy is restricted in 1995 [12]. Unlike co-methoxazole 
trimethoprim (TMP-coMX) combination therapy, TMP-SMX combination therapy 
thought to be a better alternative and claimed that this drug combination via their 
synergistic effect is also decreasing the rate of evolution of resistant bacteria [13].  
 Trimethoprim has very high binding affinity to prokaryotic DHFR when 
compared to its eukaryotic ortholog[14]. When E. coli DHFR gene is blasted in non-
redundant database against mammal proteins, the best alignment has the sequence 
identity as 30%. This affinity and sequence difference also makes trimethoprim, a good 
antibiotic candidate.  
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5.8. Resistance Mechanisms against Folic Acid Biosynthesis Pathway Inhibiting 
Antibiotics  
 
 Figure 5: DHFR enzyme 3D structures taken from different species. Top Line: 
Bacillus anthrasis, Candida albicans, Mycobacterium tuberculosis, Center: Escherichia 
coli, Bottom Line: Gallus gallus, Mus musculus, Homo sapiens 
  
 Although Trimethoprim resistance is a highly studied issue, the problem hasn’t 
been completely solved yet. General pathways that are mentioned for becoming 
resistant to the antibiotics are also applicable for TMP. For example, S. aereus and S. 
pneumoniae have insensitive DHFRs in their metabolisms. Another defense mechanism 
found in P. aeroginosa, these gram-positive bacteria, has cell wall structure that doesn’t 
let TMP enter the cell. The highest level of resistance is acquired by mutating DHFR 
gene and also in literature, E. coli cells which bears mutant folA gene, have resistance 
level up to solubility limit of TMP in media. In their paper, Toprak et al, explains how 
mutations occurring on regulatory and/or coding region of folA gene make insensitive 
E. coli cell against Trimethoprim stress [15]. Their paper is mainly focused on the 
genome. Though, TMP resistance issue has genomics causes, but because of 
competitive inhibition of DHFR, the main reason why cell become resistant is because 
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TMP can’t stop the kinetics of the enzyme. In this project, main aim is to understand the 
resistance issue as protein stability and an enzyme kinetics problem.   
5.9. Morbidostat  
 Morbidostat is a continuous bacterial culturing device to understand the 
evolutionary constraints of different stress conditions [16]. This device automatically 
allows us to monitor the growth of cultured species under different continuously 
changing antibiotic concentration with respect to resistance levels. Thus, besides the 
growth rate and drug concentration at a certain time period, resistance level at certain 
time can also be measured. How morbidostat works is simply illustrated in the figure 
taken from the Nature Protocols paper of Dr. Toprak and his colleagues [15, 16]. 
Bacterial growth is measured with detectors located in tube holders periodically such as 
in every second. If growth curve in a period exceeds the limit OD or slope of the growth 
curve in that period exceeds certain limits given by the user, machine adds stock 
antibiotic solution to the culture tube. Volume of culture is kept under control by taking 
excess amount of culture out of the tube regularly. Thus, by adjusting the type of 
antibiotic added, amount of antibiotic added, and upper-lower limits of growth; 
different stress conditions can be studied in morbidostat easily. There are also other 
potential applications for morbidostat, such as host-pathogen interactions, long-term 
adaptation experiments, or drug resistance in cancer cells.  
Figure 6: Controlling algorithm schema showed in Toprak et al paper. [15, 16] 
5.10. Statistical Coupling Analysis (SCA) 
 Statistical Coupling Analysis (SCA) is a tool for showing the sparsely and 
contiguously spaced and interacted groups of aminoacids found as a blueprint of natural 
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proteins and these groups of residues are called sector [17-20]. This tool provides co-
evolved residues of proteins that are important for function and proper folding of them 
[17-20]. Sector residues are spanning through the 20% of the protein and they are 
physically linked with each other. Recent studies on SCA showed that sector regions 
spanning through the protein makes a communicative network between allosteric and 
active sites of the protein so that mutations on one site of the proteins can be 
compensated with other mutations on the other site of the proteins. Thus folding and 
function can be regained appropriately [18]. McLaughlin et al, in their Nature paper 
explained analysis and the construction of the SCA matrices in detail. As a brief 
explanation of how SCA find evolutionarily driven residues is that SCA needs sufficient 
amount of multiple sequences from different sources of organisms and size of the 
alignment can vary by the question of interest. Then to construct the SCA matrices the 
conservations of each pairs are used with the normalization of randomized shuffling of 
these pairs on their multiple sequence alignment columns. After this normalization 
eigenvectors of each columns are calculated and graphed as color-coded matrix. This 
matrix is n by n and the n is the number of sequences aligned. There are some hotspots 
found on the SCA matrices that highly red areas showing the groups of residues 
coevolved with each other (sector sites). With changing the n and the sources of these n 
sequences, sector regions allow us to see insights of evolutionary architecture of 
proteins. For instance, it can be seen that some functionalities are conserved in some of 
the branches of organisms, also some structural patterns can be seen all the related 
proteins found in literature.  
6. MATERIALS & METHODS 
6.1. Buffers, Media Solutions and Preparations 
M9 Media  
 M9 defined media is used for morbidostat experiments to decrease the 
artifacts coming from environment. Media is prepared with M9 media salts, 
0.4% Glucose, 0.2% Protein Hydrolysate Amicase, 2mM MgSO4, and 
100uM CaCl2. 
 
TB Media 
 This media is used to grow the cells for protein purification and 
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protein synthesis induction. 900mL of this medium is 12g of Tryptone, 24g 
of Yeast Extract, 4mL of 99% Glycerol is mixed with 100mL of TB salts -
0.17M KH2PO4, and 0.72M K2HPO4- [21].  
 
Ni-NTA Agarose Beads 
 For DHFR protein purification, Ni-NTA Agarose Beads were used 
(purchased from QIAGEN Firm).  
 
Ni-NTA Binding Buffer 
 This buffer is used to bind the His6-tagged DHFR to the Nickel beads 
designed for protein purification. Buffer includes 50mM Tris-HCl, 10mM 
Imidazole, 0.5M NaCl. pH is adjusted to the 8.0. 
 
Ni-NTA Elution Buffer 
 To elute the bound proteins from the Nickel Beads, this buffer is used 
and it composed of 100mM Tris-HCl, 400mM Imidazole, 1M NaCl. pH is 
adjusted to 8.0. 
 
Dialysis Buffers for Kinetics Experiments 
 Dialysis process is important for DHFR enzyme kinetics because 
Imidazole in Binding and Elution buffers absorbs the light at 340nm like 
NADPH does [22]. Thus imidazole in protein solution has to be minimized 
before Kinetics measurements. Buffer designed for Kinetics experiments 
includes 50mM Tris-HCl, 300mM NaCl and 1% Glycerol. pH for this buffer 
is also 8.0. 
 
Dialysis Buffer for Differential Scanning Calorimetry (DSC) Measurements 
 Tris-HCl buffer is very sensitive to the temperature changes. Thus, the 
dialysis buffer used for Kinetics experiments is not suitable for DSC 
experiments. Therefore, another dialysis buffer is used for stability 
measurements that composed of 10mM Potassium-Phosphate Buffer, 
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0.2mM EDTA, and 1mM β-Mercaptoethanol solutions with pH 8.2.  
 
MTEN Buffer 
 For kinetics measurements MTEN buffer is used for Kinetics 
measurements of DHFR such as Km, Kcat, Vmax, KI. Buffer includes 50mM 
MES, 25mM Tris-Base, 25mM Ethanolamine, 100mM NaCl. 5mM fresh 
DTT is added at the beginning of the assays. pH is 7.0. 
 
Dihydrofolic acid (DHF) and NADPH solutions 
  25 mg of DHF is mixed with 10 mL of MTEN buffer (pH 7.0) and 
35µL of β-Mercaptoethanol. Quantitation of DHF is done in A282.  
NADPH solutions are prepared with adding 8mg of NADPH powder into 
1.5mL of pH7.0 MTEN Buffer. Concentrations are measured in NanoDrop© 
machine at 340nm. Both solutions are stored in -80 ℃ for further use.   
 
6.2. Morbidostat Experiment Setup for TMP resistance 
 To be able understand the affects coming from the selection strength; two 
different selection environment is used in this study. First group has 7 different cultures 
and has the dilution rate of 0.6h-1 –a.k.a. strong selection- and the second group has 6 
different cultures and their selection rate 0.3h-1 – a.k.a. mild selection-.  In other words, 
for strong selection ~60% of the culture is changed with whether stock antibiotic 
solution or media and for the mild selection this rate is about 30%. To reach this 
dilution rates, strong selection has 60 seconds of drug or media injection; moreover, in 
mild selection injections last 30 seconds.  
 
6.3. Morbidostat Replay Experiment Setup  
 To verify the results, morbidostat experiment is repeated with a single mutant as 
new parental strain. This regulatory site mutation is commonly popped up at the 
beginning of the first experiment (c-35t).  In literature, this mutation is known to 
increase the expression of DHFR [23]. Setup for the experiment is the same as first one 
i.e. there are two different selection conditions called strong and mild and the 
experiments lengths are 5 days and after experiment single colonies are picked and sent 
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to sanger gene sequencing.  
 
6.4. Sanger Sequencing and SNP analyses 
 Sanger sequencing is done with the help of Genewiz®. For this experiment more 
than a thousand colonies are picked and sequenced for their folA coding and its cis-
regulatory region.  To analyze the results, CLC Biology MainWorkbench and 
MacVector softwares are used. In these programs, one can easily align the query 
sequence to the reference WT folA sequence. After analyzing the alignment with 
respect to reference, SNP positions are determined and included in results section.  
 
6.5. Heterogeneity or Diversity Calculations 
After each day of the morbidostat experiment bacterial cultures are taken for 
further usage and analyzed to reveal the daily changes on the folA gene. These daily 
changes are shown as trajectories and diversity of the daily trajectories are calculated 
with the formula below: 𝐷𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦  𝑆𝑐𝑜𝑟𝑒  (𝐸𝑛𝑡𝑟𝑜𝑝𝑦   𝐻 ) = 𝑓!!!!! ln 𝑓!  
 In this formula n represents the number of different genotypes; p,q,r are the ratios 
of the each genotype found after analyses of multiple sequences for each days. To make 
this more understandable lets make two different examples. 
1. If there is only one mutant found after sequencing: 𝐻 = 1 ∗ ln 1 = 0 
So there is no diversity in the environment.  
2. There are three different mutants in one day and ratio for one of them is 50% and 
the other two are 25% each: 𝐻 = 12 ∗ ln . 5 + 14 ∗ ln . 25 + 14 ∗ ln . 25 =   1.03   
Thus the diversity increased from 0 to 1.03.  
6.6. Site Directed Mutagenesis and Colony Screening Protocol  
 To make new single mutant colonies, QuickChange® site directed mutagenesis 
protocol have been used. In this protocol, complete homologous primers are used and 
they just have one nucleotide changed from wild type to be able to make targeted 
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mutation. For this purpose, the mutated primers are designed and ordered from IDT 
DNA Technologies®. In this protocol, plasmids including the target gene are amplified 
with using mutated primers (forward and reverse). Then plasmids, which are already 
methylated, cleaved by an enzyme called Dpn1. What is specific for this enzyme is that 
this enzyme only recognizes a palindromic region that has methylated residues on it. 
Thus, newly synthesized plasmids cannot affect from incubation with enzyme. All the 
end products of this amplification and incubation processes are transformed in a 
plasmid compatible cell line and plated on a selective media plate. This protocol and 
reagents are found as a kit from Agilent Genomics firm but two of the Ranganathan lab 
members optimized the protocol for non-kit users as described above. Detailed 
protocols found in this reference [24]. 
 Although incubation with enzyme cuts out all the WT plasmids, to make sure that 
plasmids have the intended mutation, colonies found on the selective plates are 
screened, and Sanger sequenced.  
 
6.7. Plasmid Isolation Protocols (Boiling Mini Preparation Protocol) 
 To isolate mutant plasmids produced in QuickChange step, traditional phenol-
chloroform plasmid isolation protocol is used. Detailed protocol for this part is found in 
the AddGene webpage. [25] 
 
6.8. Homologous Recombination Protocol 
 Recombineering protocols are used in this step. In recombineering protocols, 
query gene is designed with having homologous arms in two ends so that when bacteria 
started to polymerize the DNA query gene is also amplified and added into the genome 
of interest. Detailed protocols are found in the references [26-30].  
 
6.9. Protein Purification Protocol  
 Purification of the protein is necessary for making biochemical assay and the 
purer the protein, the better the results. To make this happen pet24a plasmid is used. 
This plasmid has T7 promoter, lac operator and his tags on it. Thus when induced with 
IPTG (inducer of lac operator), folA gene found between his tag and T7 promoter is 
expressed in high amount at lower temperatures of incubation. To purify the proteins 
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Ni-NTA Agarose beads are used (Ordered from QIAGEN). These beads have high 
affinity to bind His-tags; hence high purity can be achieved with these steps.  
 
6.10. Enzyme Affinity Assay and Km,  Vmax , Kcat calculations  
 For these measurements GraphPad Prism© software is used. In this software, first 
one-fourth of the A340 vs. Time data coming from Spectrophotometry instrument is 
nonlinearly regressed and slope values are used for Michelis Menten Kinetics 
calculations. This software has the feature for the data needs for nonlinear fitting such 
as Michelis-Menten curves. Kcat values are calculated by following formula: 𝑉𝑚𝑎𝑥𝜖!"#$% = 𝐾𝑐𝑎𝑡 ∗ 𝐸𝑛𝑧𝑦𝑚𝑒  𝐾𝑐𝑎𝑡 = 𝑉!"#𝐸𝑛𝑧𝑦𝑚𝑒 ∗ 𝜖!"#$% 𝜖!"#$% = 12.300𝑀  𝑐𝑚!! 
6.11. Enzyme Stability Assay 
 For this assay Differential Scanning Calorimetry is used. Main logic in this assay 
is to cover a wide range of temperature interval to monitor the required enthalpy to 
stabilize the temperature of the cell. In this assay no inhibitor used. Stabilities of empty 
proteins (WT and mutant counterparts) are measured.  
 
7. RESULTS 
 
7.1. Morbidostat Experiment Results  
After 28 days of evolution experiments, all the OD growth graphs are collected and 
linked end to end. To briefly explain the working mechanism of morbidostat, figure 
below added. Every 18 mins, controlling algorithm runs and decides which pump to 
open separately for each culture and adds media, antibiotics or neither. Green circles 
show where media pump opened; red circles show where low concentrations antibiotic 
injection started, and purple circles show where high concentration antibiotic injection 
started. Respectively triangles showing the closing of each pumps. All opening and 
closing are controlled by algorithm explained in deep in Toprak et al. Nature Genetics 
and Protocols papers [15, 16]. Red and Purple Line shows the OD point where 
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respective antibiotic addition starts. After certain amount of time bacteria start to 
become resistant to antibiotic concentration added and growth start not to influence 
from that concentration of antibiotic addition. Continuous average OD increase between 
120th and 130th hours coming from this resistance level increase. But after highly 
concentrated TMP addition –shown as purple pump opening-, population size is highly 
shrunk. Next figure series are showing the whole experiments done for all 7 strong and 
6 mild selection replicates.  
 
Figure 7: An example time interval of working Morbidostat experiment. Circles are 
showing the pump openings and triangles underneath each circle show when respective 
pump is closed.  
 
Figure 8: Whole experiment shown for one culture of Mild Selection 
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Figure 9: Whole experiment shown for one of the strongly selected cultures. 
 
Whole experiment graphs for other 11 cultures are put in Appendix. By analyzing the 
fluctuations in trimethoprim concentrations in the culture tubes, bacterial resistance 
levels are monitored. Graphs below show changes of trimethoprim in time course for 
one mild and one strongly selected culture. 
Figure 10: Mildly selected colonies generally show this stepwise increasing pattern. 
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Figure 11: Clonal interferences revealed in strong selection make stepwise pattern 
disappear. Thus, resistance levels are increasing sharper in strong selections.  
 
Change in TMP concentrations for other colonies are put in Appendix. Also to see the 
general picture for the TMP concentrations next graph is plotted. This graph shows 
change in TMP concentrations by selections. It is clearer to see that in mild selection 
populations have been increased their resistance levels in more than one-step. Unlike 
mild selection, in strong selection conditions daily fluctuations of trimethoprim is 
sharper.  
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Figure 12: Left graph shows the TMP change in mild selection and the right graph 
shows the strongly selected colonies. 
 
Growth rates and changes in drug concentrations are calculated with using adjacent 
pump closings and openings. All figures for growth rate changes shown for both 
selections and error bars show standard deviations between the cultures.  
 
7.2. Growth Rate Measurements of Daily Samples  
Growth rates for daily samples are also measured with TECAN® that is a specialized 
instrument for 96 well plate growth readings. Graphs are plotted with respect to 
selections. Red Circles indicates the growth rate at a certain day for strong selection and 
the blue circles are showing the mild selection. Results show that in both selections 
growth rates of mixed populations daily taken from the experiment is not affected and 
the values are similar for both selection conditions. It is important to note that 
fluctuations seen as error bars in strong selection is bigger than mild selection. Reason 
for these bigger fluctuations is tried to explain further in discussion section.  
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Figure 13: Growth Rates for daily mixed populations measured in 96 well plate reader 
instrument. This experiments are done in TMP free conditions. 
 
7.3. Sequencing Results and Mutation Trajectories 
Figure 14: Mutations found on cultures on final day of experiment. 
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 Throughout the Morbidostat experiment, to avoid biofilm formation at the walls 
of the culture tubes, after each day small amount of culture (~100 µL) taken and diluted 
in fresh media and experiment continued for next day. Also mixed populations are taken 
and stocked in 50% glycerol for further use. After the experiment, these daily mixed 
populations are plated and 4-12 single colony sequenced for each day and each culture. 
Totally ~1500 single colony is Sanger sequenced for their folA promoter and coding 
region in this study. To show all the sequencing results special cylinder graphs are used 
and these trajectories shows the mutations gained in time course. Starting from the left 
first rectangle days are shown on the base part of the graphs. Each big cylinder shows a 
genotype shown on that day. Top of the each cylinder there are circles on the center and 
cylinders at the periphery. Central circle shows the promoter mutations and peripheral 
cylinders shows the coding region mutations. Each radial angle is specific for a 
mutation. Also these peripheral cylinders are shown like pie charts i.e. colored part of 
the pie chart shows the percentage of the single colonies seen as that genotype. Also one 
of the cultures acquired two promoter mutations at the same time and this genotype is 
plotted as diamond on top of the central circle.  
 
 
 
Figure 15: Genotypic Diversity found in first culture in mild selection 
 
When we look at the Figure 13, diversity seen only on day 13 and it lasts just 1 day after 
the day 13, all the colonies seen has the same genotype till the end of the experiment.  
Figure 16: Genotypic Diversity found in second mildly selected culture 
Also for the other mildly selected culture diversified state continues only for three days.  
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Figure 17: Genotypic Diversity seen in of the Strong Culture 
 
 
Figure 18: Clonal Genotypic Interference found in other strongly selected culture 
Cultures of the both selections there are significant difference in diversity of genotypes 
and the duration of these diversities are more common in strongly selected cultures than 
mildly selected cultures. These graphs are plotted in VPython module of Python 
language. Scripts for these plots can be given with request. Genotypic Diversity Graphs 
for all other cultures are found in appendix part.  
 
7.4. Diversity Plots  
To quantitate the diversity found on genotypes of cultures, F statistics are optimized for 
haploidic genotype structure of bacteria. Detailed explanations on Diversity scores can 
be found in Materials & Methods section.  Diversity scores for each culture are plotted 
and added below.  
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Figure 19: Plot shows the Diversity score for each day of the experiment. Arrow shows 
the day of diversity found in mild selection culture. 
 
 
Figure 20: Plot shows the diversity and cylinder graph shows the genotypes found on 
that day.
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 Figure 21: Diversity scores by selection strength 
These two figures show the diversities as groups of selections and the error bars show 
the standard errors of diversity scores in days. Straight line in both figures, show the 
mean diversity score for that selection. This graph apparently shows the score for 
diversity is really high in strong selection. Also diversity continues to day 14 in strong 
selection but in strong selection it lasts one more week to genotypically stabilize the 
population.  
Figure 22: Durations for diversified populations 
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 Lastly, the durations of genotypic diversities found on selections are compared 
and this bar graph is plotted for this purpose. Error bars on these histograms show the 
standard errors in replicates in selections. As a result, cultural diversity in strong 
selection surprisingly more common and lasts longer than mild selection conditions.  
 
7.5. Whole Genome Sequencing (WGS) Results 
 Each culture final days are sent WGS and results revealed that main cause for 
TMP resistance is coming from the mutations on folA gene regulatory or coding site. 
Detailed table for WGS results added as Appendix. 
 
7.6. Biochemical Assays on Single Mutant DHFRs 
 Results of these genomic studies showed that amount of DHFR and whether the 
change of stability or the change on catalysis rate of enzyme is important to become 
TMP resistant. Hence, to understand the biochemical changes found on DHFR enzyme, 
single mutant genes are made and expressed in E. coli cells. After purification of the 
single mutant enzymes, biochemical assays below are done.  
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7.6.1. Binding Affinity Measurements and Enzyme Catalysis Rate Calculations 
 Table 1: Binding affinity and Catalysis Rate values for DHFR enzyme single 
mutants 
 
 Details about measurements are explained in Materials & Methods section. 
Reaction catalyzed by DHFR enzyme occurs really fast and all mutants are analyzed by 
their Km values for substrate of the enzyme (Dihydrofolate-DHF). Figures showing the 
catalysis rates are put in the appendix. Here is the table showing the results of Binding 
affinity and catalysis measurements.  
 
 Binding affinity assays also gives the Vmax for the enzyme. Thus, turn over 
numbers for the enzymes can be calculated. But to assess the differences of catalysis 
Kcat/Km is a better measure used in literature.   
As listed on the table above, catalysis of DHF molecule can be increased up to ~20 
fold. These results reveal that increase in catalysis rates is one of the reasons that help to 
become resistant.  
Mutant 
Name 
Km (nM) Kcat (1/sec) 
Kcat/Km 
(1/sec.mM) 
Fold 
Change 
WT 1.233 0.589 477.697 1.000 
A26T 3.880 2.359 607.990 1.273 
P21L 3.994 3.567 893.090 1.870 
W30R 8.731 10.496 1202.153 2.517 
I94L 2.736 4.870 1779.971 3.726 
W30G 1.986 4.095 2061.934 4.316 
W30C 1.847 5.564 3012.453 6.306 
L28R 0.163 1.415 8702.337 18.217 
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7.6.2. Effects of TMP on Catalysis  
  
Figure 23: This figure shows the fold change in affinities of DHFR single mutants to 
antibiotic TMP.  
  
 Figure above indicates that A26T and L28R mutations decrease the affinity for 
TMP so that these proteins are more insensitive to TMP when compared to wild type 
protein. Interestingly, P21L mutation slightly more sensitive to TMP; although, this 
situation explains why there are no P21L mutations seen at the end of the experiments, 
why this mutation is repeatedly acquired in different cultures and different days of 
experiment is still unknown. 
7.6.3. Protein Stability Results 
As explained before, stability of the proteins are measured in Differential Scanning 
Calorimetry instrument. Tm values of the mutant proteins generally have similar values 
except W30R and W30G. These results give a brief intuition why W30R and W30C 
mutation bearing cultures are eliminated by L28R mutation bearing clones in culture 14 
(See appendix for this result). Also when they compete with the other mutations 
generally they acquire other mutation to make conditions even. Thus they can survive.   
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Figure 24: Stabilities of Mutant Proteins are compared with wild type. Gray area shows 
all standard deviation of database of mutations. Error bars are coming from the 
individual fits. 
 
8. DISCUSSION 
 
8.1. What have been learned from Morbidostat results? 
 
 Morbidostat result graphs for each culture shows that in mild selection conditions 
there are stepwise increase in resistance levels unlike the sharp increase in strong 
selection conditions. Also when drug concentration changes are analyzed in both 
selections, there is a distinct pattern. For strong selection, drug concentration increase 
occurs immediately after pumps open and population size is shrunk and later injections 
decrease the concentration of drug in culture immediately. On the other hand, in mild 
cultures, drug concentration changes slowly.  When the scope is turned to molecular 
picture, Trimethoprim is specifically affects the regulation of folA gene. When all the 
final genotypes are investigated only three-four folA mutations are enough for 
bacterium to become completely insensitive to antibiotic. To understand the 
mechanisms against the selection strengths further experiments are needed. Since in 
both selection conditions, growth rates are not completely affected (see figure 12). It is 
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hard to completely compare and contrast the big picture with this two dilution factors. 
In fact, to completely understand the affect of short but dense pulses of antibiotic 
injections at least dilution factor’ of 0.8 is needed to be done and analyzed. Also for the 
mild selection conditions to be able to compare and see complete difference of long 
sparse pulses i.e. lower dilution factors such as .2 or .15 have to be done and analyzed.   
 
8.2. Why the mutation trajectories are changing in different selection conditions? 
 Although, final day results are not showing any difference in different selection 
strengths, progression for becoming resistant is highly different between selection 
strengths. As shown with the cylinder graphs, diversities among the strong selection 
cultures are more common than mild selection cultures. These results are kind of 
unexpected because when the dilution factors are thought, in each hour, strongly 
selected populations lose their ~60% of their population size unlike this number is 
~30% in mild selection conditions. Thus, an expected result for this experiment was the 
exactly the opposite; however, drug concentration changes in strong selection 
conditions are highly dynamic that the concentration increases sharply and decreases in 
an instant. Dynamic changes found in strong selection environment doesn’t let the 
different genotypes to compete and stabilize in one genotype. On the contrary, mild 
selection conditions are changing slower and genotypic interference for different 
bacteria are diminished because of the difference in fitness of these different genotypes. 
Also in mild selection conditions, bacteria that have higher fitness have time to 
dominate the environment and sequencing results just shows that one genotype in most 
cases. Moreover, to prove this concept, single DHFR mutants are necessary and their 
growth rates’ had to be measured. This part of the project is work in progress.  
 
8.3. Orders of Mutations on DHFR related to TMP resistance 
 To understand the response of the bacteria chronologically under TMP stress, it is 
needed to generalize the mutations acquired by bacteria. 12 out of 13 cultures first 
mutation acquired is on the promoter mutation. That mutation is required for 
overcoming the affects of TMP. The simplest strategy for overcoming the competitive 
inhibition effect, bacteria increase the number of DHFR protein with promoter 
mutation. There are many both clinical and basic science studies showing the c-35t 
mutations that we also seen is increasing the amount of DHFR expressed in the cell [23, 
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31]. This first mutation doesn’t have a direct effect on protein structure and function. 
Only the amount of mRNA and protein is changing. Since environment is overwhelmed 
with high concentrations of TMP, bacterium has no choice to mutate the coding part of 
the gene. Albeit, these whole processes occurs randomly, fitnesses of these promoter 
mutants are not enough to dominate the environment or the inhibitory effects of high 
concentrations of TMP starting to become enough to kill the whole population. Hence, 
bacteria repeatedly chose to mutate some residues that they are more related to SCA or 
sector positions on DHFR. 4 out of 5 first popped up mutation is on the sector position. 
But after first mutation, it is very hard to predict the location of next mutation. When 
sector regions are extended with the secton positions on the DHFR protein, almost all 
the antibiotic resistance related mutations are occurring on these regions. This 
hypothesis is tested with Two Tailed Fisher’s Exact Test, albeit, p value is slightly 
higher to .05, if we can achieve to increase the database of both sector regions of 
resistance related proteins and the mutations acquired to become resistant this value will 
be lowered and become significant. To further understand the nature of the resistance 
related mutations biochemical properties of these single mutant proteins are examined. 
8.4. What are the effects of single mutations on DHFR activity?  
DHFR is an essential enzyme for E. coli. After examining 7 single mutant by their Km 
and Kcat values, results show that other than L28R mutations, mutant proteins decrease 
their affinity to bind DHF. Despite their increased Km values when compared to wild 
type protein, all mutations have higher catalysis rate (Kcat/Km) than wild type. These 
results explain why these mutations are acquired and stayed. Since their catalysis rates 
are higher than wild type, they can endure the reaction catalyzed by DHFR at higher 
concentrations of TMP. In this part also there are missing experiments, for example, 
biochemical assays for newly found mutations in our Morbidostat experiment has to be 
done. What we have now in our hand is also briefly says that mutations like A26T is not 
good at both protein stability and binding affinity but this mutation decrease the affinity 
of DHFR to TMP up to 8 fold. Thus, this explains why bacteria generally acquire A26T 
mutations through the end of the experiment because desensitization of DHFR is more 
important because TMP concentration is gone really high. This observation is also valid 
and seen in Toprak et al Nature Genetics paper. L28R mutation was a very strong 
mutation found in 9 out of 13 cultures, is also biochemically-desired mutation. Since the 
catalysis rate of L28R mutation is about 20 fold higher than the wild type protein and 
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the affinity of this mutation to TMP is about 5 fold lower than wild type. Thus having 
L28R mutation is highly possible and highly advantageous for bacterium. Also protein 
stability data showed why W30R mutation found in culture 14 is dominated with L28R 
is the stability issue. Though, W30R mutant has higher catalysis rate about 2.5 fold, it 
has lower stability values than the other mutants that are analyzed, thus this mutation is 
replaced with other mutations in mixed populations. When biochemical assays for the 
other single and some interesting double mutants are analyzed our understanding of 
resistance related mutations would be increase.  
 
9. CONCLUSIONS 
 
9.1. Morbidostat Results and Implications  
 Morbidostat experiment shows us that wild type bacterium is not really far away 
from being completely insensitive to TMP. One promoter and two-three coding region 
mutations on DHFR are making bacterium resistant to trimethoprim up to its solubility 
level. This study is important to understand the effects of environmental changes such 
as dilution rates cause differences in diversity of populations genotypes. Pulse rate, 
length and the concentrations are important in population genetics of the bacterial 
culture. For instance, short but high concentration pulses of antibiotic injections 
preserve diversity more than long and sparse pulses. Main logic behind this observation 
is long and sparse pulses makes high fitness bacteria to dominate the environment and 
stabilize the genotypic diversity. To understand the diversity, an optimization of F 
statistics is used.  
9.2. Orders of Mutation and Further Understandings 
 Other than general Morbidostat results, genomic studies and biochemical studies 
revealed that main cause for TMP resistance is mutations acquired on folA gene 
regulatory and coding region. Generalizations on these mutations and their locations 
showed us that first rule for overcoming the competitive TMP resistance is acquiring 
promoter mutations. Second rule is to mutate the sector regions so that function and the 
folding of the protein can change and makes TMP an undesired mimicking molecule. 
After second rule, epistasis of genes have important role that needs to be understood 
further. Since biochemical observations are preliminary we can only say that bacteria 
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wants to overcome the stress with changing the biochemical parameters of DHFR such 
as Km, Kcat, Stability.  
 
 
10.  FURTHER WORKS 
10.1. Mutant genes and their impacts on cell 
 To understand the fitness effects of each mutation on DHFR, mutations are 
homologous recombined and put into the genome. Thus all the effects of mutant 
proteins can be monitored by the means of fitness and growth rate. Also their resistance 
levels against TMP and cross-resistance levels against other antibiotics would be 
assessed. These allow us to understand whether there are some cross talks between the 
folate pathway and the other antibiotic resistance related pathways. Also is there any 
other missed cause for TMP resistance other than mutations on folA. 
10.2. Single and Double mutant proteins and their activities 
 Single mutant proteins that are novel literature, we couldn’t have time to express 
and measure their activity.  Also some of the double mutant proteins would be 
interesting to study and understand the evolution of antibiotic resistance. For example, 
after characterization of each single mutant we may choose one highly desirable and 
one highly defective mutation and make double mutant protein. These allow us to find 
out the rules of epistasis DHFR have and what makes natural selection to acquire these 
mutations on top of each other.  
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 12. APPENDIX 
12.1. Whole Morbidostat Results for all Cultures 
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12.2. TMP concentration change with respect to time 
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12.3. Cylinder Graphs 
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12.4. Diversity Scores by Cultures 
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12.5. Km Plots 
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12.6. Ki Plots 
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12.7. Stability Plots 
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